Quick Answer
Tarsus Pharmaceuticals, Inc. reported Cash and Equivalents of $224.95 million for fiscal year 2023.
Tarsus Pharmaceuticals, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2023 | $224.95M | +213.9% |
| 2022 | $71.66M | -58.2% |
| 2021 | $171.33M | +1.9% |
| 2020 | $168.13M | +190.1% |
| 2019 | $57.95M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| June 30, 2022 | $245.36M | +38.8% | +40.2% |
| March 31, 2022 | $175.01M | +12.1% | +2.1% |
| December 31, 2021 | $171.33M | +1.9% | -6.8% |
| September 30, 2021 | $183.80M | +112.9% | +4.0% |
| June 30, 2021 | $176.74M | +232.6% | +13.2% |
| March 31, 2021 | $156.18M | +179.4% | -7.1% |
| December 31, 2020 | $168.13M | +190.1% | +94.8% |
| September 30, 2020 | $86.33M | +25516.9% | +62.5% |
- Tarsus Pharmaceuticals, Inc. showed an increase of +213.9% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2019–2023 period, Tarsus Pharmaceuticals, Inc.’s cash and equivalents has grown by 288.2% (from $57.95 million to $224.95 million).
- The most recent figure is from Tarsus Pharmaceuticals, Inc.’s fiscal year 2023 report (Form 10-K), filed with the SEC on February 27, 2024.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: